◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral STRONG-CANDIDATE MEDIUM

Armodafinil

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict STRONG-CANDIDATE MEDIUM

Reasonable A/B-test candidate vs modafinil for Dylan but the longer late-day plasma tail and 3-4hr later Tmax make it riskier for a late chronotype migrating to midnight bedtime; modafinil 100 mg AM remains the safer daily-driver default. Verdict would shift to OPTIONAL-ADD if A/B test shows modafinil insufficient duration past 3 PM, or to SKIP-FOR-NOW if armodafinil pushes sleep onset past 1 AM in week 8-12 trial.

Research pass: thorough
▸ Subjective experience (deep)

Onset: 60-90 min after fasted dose; 2-4 hr if taken with food. Peak effect window: 3-6 hr post-dose for cognitive enhancement. Effective wakefulness window: 12-14 hr.

Characteristic feel:

  • Less of a "kick" or "peak" than modafinil — described as a smooth elevation with no euphoric edge
  • More "glide" through the workday with steadier focus
  • Less of the modafinil "afternoon shoulder" (the slight dip when S-enantiomer clears)
  • Late-day persistence: at 6-8 PM, plasma armodafinil is meaningfully higher than equivalent modafinil; users notice they are "still on" much later
  • Some users report it feels more like a clean alertness, less anxiogenic than modafinil for them; others report the opposite (more anxious because longer)
  • Cognitive enhancement (decision-making, planning, sustained attention) appears equivalent to modafinil in healthy users; benefits more pronounced in sleep-restricted than well-rested individuals

Variability: High inter-individual variation. Frontiers in Pharmacology 2025 (Hansen et al.) showed stable interindividual differences in modafinil vigilance response — same person responds consistently across exposures, but between-person response varies substantially. CYP3A4 induction status, CYP2C19 polymorphism, body mass, and prior caffeine adaptation all modulate.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: minimal-to-low. This is one of armodafinil's strongest selling points. 12-month open-label data shows wakefulness improvements maintained from month 1 throughout study. Narcolepsy patients use daily for years without dose escalation.
  • The tolerance debate: Clinical data consistently shows no meaningful tolerance for therapeutic narcolepsy/OSA use. Anecdotal nootropic-community reports of "modafinil tolerance" likely reflect (a) initial novelty effect fading, (b) sleep debt accumulation that the drug masks, or (c) genuine but modest receptor desensitization with very high-dose chronic use. The 2023 study on pitolisant-bridging for "modafinil tolerance reset" exists but doesn't establish that conventional armodafinil tolerance is a real phenomenon at therapeutic doses.
  • Recommended cycle for Dylan: 5 days/week (M-F) with weekend washout to preserve receptor sensitivity and verify no sleep-debt masking is occurring. This matches modafinil cycle protocol.
  • Reset protocol if needed: 7-10 day full break is sufficient to clear any tolerance. Some users implement a 1-week pause every 8-12 weeks as insurance.
▸ Stacking deep dive

Synergistic with

  • caffeine (low dose, 50-100 mg): Adenosine antagonism is mechanistically additive to dopamine/orexin/histamine arousal. Dylan baseline has zero caffeine, so 50 mg with armodafinil could be a strong combo for high-output mornings — but stack caution because both extend wakefulness window.
  • L-theanine 200 mg: Smooths the alerting edge, no efficacy compromise.
  • bromantane: Different mechanism (mild DA + 5-HT + DAT, anti-asthenic). Stacks cleanly per Russian eugeroic protocols. This is part of Dylan's V5 plan.
  • citicoline / Alpha-GPC: Cholinergic substrate support for the cognitive load that modafinil-class drugs let you sustain.
  • bupropion (if Rx-path): 6 RCTs back modafinil + bupropion for depression/fatigue; same mechanism logic applies to armodafinil + bupropion.
  • omega-3 / DHA: General brain substrate; no interaction.

Avoid stacking with

  • MAOIs (selegiline >10 mg, tranylcypromine, phenelzine): Hypertensive crisis risk. Note for Dylan: Selegiline 1-2.5 mg/day is MAO-B selective only and clinically considered safe with modafinil-class drugs, but stay below 5 mg/day strictly to avoid losing selectivity. The V5 plan's selegiline 1-2.5 mg AM is fine; do not escalate.
  • classical stimulants (amphetamine, methylphenidate, focalin): Stacking dopaminergic stimulants → overstimulation, cardiovascular load, anxiety, sleep wreck. Pick one.
  • 9-Me-BC + bromantane + armodafinil triple-stack: 3 dopaminergic agents = overstimulation risk per encyclopedia.
  • other eugeroics (modafinil, solriamfetol, pitolisant): Redundant + AUC stacking. Pick one wakefulness anchor.
  • hormonal contraceptives (irrelevant for Dylan, but flag): CYP3A4 induction reduces effectiveness ~18%.

Neutral / safe co-administration

  • All of Dylan's V4 stack: NAC, citicoline, magnesium glycinate/threonate, fish oil/DHA, phosphatidylserine, curcumin, rhodiola, theanine, glycine/tryptophan, D3+K2, beta-alanine, vitamin C — no known interactions
  • Creatine
  • Adamax / Semax / Selank intranasal peptides
  • Cerebrolysin IM (different pathway entirely)
  • BPC-157 / TB-500 peptides
▸ Drug interactions deep dive

Armodafinil's CYP profile:

  • Moderate inducer of CYP3A4 — reduces blood levels of CYP3A4 substrates: hormonal contraceptives (~18% decrease — primary contraceptive failure mechanism), cyclosporine, midazolam, triazolam, certain statins, certain anti-epileptics, certain protease inhibitors. Use barrier or non-hormonal contraception during therapy and for 1 month after discontinuation.
  • Moderate inhibitor of CYP2C19 — raises blood levels of CYP2C19 substrates: diazepam, phenytoin, propranolol (Dylan's PRN propranolol is CYP2D6 mainly but has 2C19 secondary path — be aware), omeprazole/esomeprazole, clopidogrel (which becomes less effective via inhibited activation), some SSRIs (citalopram).
  • Weak inducer of CYP1A2 (less clinically meaningful than modafinil's CYP1A2 induction).
  • No clinically significant effect on CYP2D6 at therapeutic doses.

Specific interactions worth flagging for Dylan:

  • Propranolol 20 mg PRN (V5 list): Armodafinil's CYP2C19 inhibition will modestly raise propranolol exposure. At 20 mg PRN this is unlikely to be clinically significant but is worth knowing if HR/BP are unexpectedly low post-presentation dose.
  • Selegiline 1-2.5 mg AM (planned V5): Below 5 mg = MAO-B selective only. Safe co-administration. Do not exceed 5 mg/day with armodafinil onboard.
  • Bupropion (if added later): Bupropion is CYP2B6 substrate primarily, no major interaction with armodafinil.
  • Caffeine: Caffeine is CYP1A2 substrate; armodafinil is weak CYP1A2 inducer. May slightly accelerate caffeine clearance — clinically minor.

Contraceptive failure risk: Highly relevant for partnered users. Increases pregnancy risk for ~1 month after discontinuation due to enzyme induction wash-out. Not directly relevant to Dylan personally but Dylan's partners (current/future) should be informed.

▸ Pharmacogenomics
  • CYP3A4 polymorphism: CYP3A4*22 carriers have reduced enzyme activity → potentially higher armodafinil exposure (and slower induction kinetics on contraceptives). 23andMe doesn't directly report CYP3A4 status comprehensively but pharmacogenomic third-party tools (Promethease, GeneSight) can.
  • CYP2C19 polymorphism: *2 and *3 = loss-of-function (poor metabolizer phenotype), present in ~3% of Caucasians. *17 = gain-of-function (ultrarapid). Since armodafinil inhibits CYP2C19, PMs of CYP2C19 substrates (clopidogrel, citalopram) experience compounded effects. Relevant if Dylan eventually takes those substrates.
  • CYP1A2 polymorphism: *1F = inducible variant, common. Dylan's caffeine response may vary based on this; armodafinil's CYP1A2 induction is mild but additive.
  • No specific HLA marker is established for armodafinil-induced SJS, unlike carbamazepine (HLA-B*1502 in Asian populations). Standard SJS surveillance applies regardless of genotype.
  • Action item for Dylan: Once 23andMe results land in June 2026, run through Promethease or similar to extract CYP3A4, CYP2C19, CYP1A2 status. Adjust starting dose downward if PM phenotype on either CYP3A4 or CYP2C19.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Indian generic (Sun Pharma — Waklert 150 mg) ModafinilXL ~$1.20-2.00/pill bulk; ~$80-120 for 30× pills incl. shipping High (operating since 2015, WHO-GMP source verified) US shipping 7-21 days; reship guarantee; crypto + card payment
Indian generic (HAB Pharma — Artvigil 150 mg) ModafinilXL ~$0.70-1.20/pill bulk; ~$50-80 for 30× pills incl. shipping High (same parent vendor, cheaper brand) Same shipping/policies as Waklert; HAB Pharma is reputable Indian generic mfg
Indian generic (multiple brands) HighStreetPharma ~$1-2/pill High (verified legit per January 2026 audit) US shipping ~21 days; EU/UK 10-14 days; functional reship guarantee
Indian generic (Waklert/Artvigil) BuyArmodafinil.com ~$1-2/pill Medium-High (reputable but smaller volume than ModafinilXL) EMS to US/UK/AU 7-12 business days; standard 10-18 days
US Rx (generic Nuvigil/armodafinil 150 mg or 250 mg) GoodRx pharmacy + telehealth Rx ~$30-60/month with insurance discount; ~$200-400/month cash High (FDA-tracked supply chain) Requires Rx; Klarity / ADHDAdvisor / LifeStance can prescribe with documented sleep complaint or shift work

Strategic note for Dylan: Order Artvigil 150 mg from ModafinilXL for first A/B test. Cheaper than Waklert with no clinical difference. 30 pills = 30 day supply if 1/day or 60 day supply if 1/2-tab. Place order ~2 weeks before week-8 A/B start to account for shipping delays. Do not co-order with modafinil shipment to keep customs profile minimal (combined orders sometimes flagged).

Vendor change since prior context:

  • BuyModa CLOSED MAY 2025 — do not attempt order from this vendor.
  • AfinilExpress closed 2019-2023 — defunct.
  • DuckDose closed — defunct.
  • Done telehealth criminally convicted Nov 2025 — defunct.
  • Cerebral dropped modafinil from formulary — paid $3.6M settlement, conservative formulary now.
  • ModafinilXL and HighStreetPharma are the two surviving high-reliability vendors as of 2026-05.

Customs note: Personal-use modafinil/armodafinil import is a gray area legally in the US. Schedule IV technically requires Rx for import, but personal-use small quantities (<90 day supply) are rarely seized; reships are typical when a package is held. Order in 30-90 day chunks, not bulk 6-month orders, to limit exposure.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Liver panel: ALT, AST, ALP, GGT, bilirubin — armodafinil is hepatically metabolized; baseline establishes any pre-existing dysfunction
  • CBC + comprehensive metabolic panel
  • Resting HR (Oura ongoing) + cuff BP
  • Sleep architecture baseline (Oura): TST, sleep onset latency, REM %, deep %
  • HRV overnight average (Oura) — 14-day baseline
  • Subjective alertness baseline scores (9 AM, 1 PM, 5 PM, 9 PM × 7 days)
  • Body weight

During use

  • Liver enzymes (ALT/AST): 8-week mark, then quarterly. Modafinil family rarely causes hepatotoxicity but worth verifying.
  • BP cuff: weekly first month, then monthly
  • Resting HR (Oura): daily — flag if >5 bpm sustained increase from baseline
  • Sleep onset latency (Oura): daily — flag if >45 min consistently
  • Total sleep time (Oura): daily — flag if loss >30 min from baseline
  • HRV (Oura): daily — sustained >10% drop is meaningful
  • Subjective alertness (logged scale): daily
  • Skin/mucosal check: weekly first 8 weeks for SJS surveillance

Post-cycle (if cycled)

  • Re-baseline sleep architecture during 7-10 day washout
  • Confirm HR/BP return to baseline within 1 week of discontinuation
  • Liver panel recheck if any abnormalities seen during use
▸ Controversies / open debates Live debate

1. Tolerance debate (resolved-ish): The clinical literature consistently shows no meaningful tolerance at therapeutic doses over 12+ months. Online nootropic-community reports of "modafinil tolerance" are confounded by sleep-debt masking, novelty fade, and selection bias. Conservative cycling (5 days/week, weekend off) is unnecessary clinically but reasonable hedge. Pitolisant-bridging for tolerance reset is a 2023 hypothesis without robust replication.

2. SJS risk magnitude: True incidence at adult therapeutic doses is uncertain — case reports exist but population-level rate is poorly characterized. Common cited figure of "~1/5000" is often pulled from broader idiosyncratic-skin-reaction post-marketing reports. The pediatric signal is more concrete (0.8% rash discontinuation rate <17yo). For 20-year-old Dylan, risk is intermediate between adult and pediatric — warrants the standard 8-week skin-watch but is not a strong contraindication.

3. Dose equivalence "feel" — does 150 mg armodafinil really match 200 mg modafinil?: Clinical efficacy data say yes (Tembe 2011). PK data say armodafinil 200 mg has ~40% higher AUC than modafinil 200 mg, suggesting armodafinil is more potent mg-for-mg, hence lower 150 mg dose at clinical equipotency. Subjective user reports diverge: many report 150 mg armodafinil feels less acute than 200 mg modafinil despite equipotent total exposure, because peak Cmax is lower and arrives later. The ~1.33× potency ratio captures total exposure, not subjective onset intensity.

4. CYP2C19 inhibition implications underappreciated: Most patient counseling focuses on CYP3A4 induction (contraceptive failure). The CYP2C19 inhibition is real and clinically meaningful for diazepam, propranolol, citalopram, clopidogrel, and PPIs — but rarely flagged in standard prescribing.

5. Pregnancy contraindication — FDA lag: EMA, MHRA (UK), TGA (AU), HC (Canada), Ireland have all required contraindication during pregnancy since 2019 due to ~13-17% major congenital malformation rate (vs 3% baseline) in registry data. FDA has not yet contraindicated. For Dylan personally: irrelevant (male user). For partners: relevant — if partner is or might become pregnant, armodafinil contraceptive-failure risk + pregnancy malformation risk = strong contraindication for partner exposure to discontinued packaging or accidental ingestion.

6. Late-day plasma persistence — asset or liability for late chronotype: Open debate within self-experimentation community. Standard logic: long-tail = good for office workers needing sustained 5 PM alertness. For late chronotype trying to migrate earlier, the long tail is the enemy of the goal. Dylan's case favors modafinil over armodafinil specifically because of this dynamic.

7. Modafinil/armodafinil and brain protection: Some evidence of neurogenesis/synaptic plasticity benefits in animal models (chronic modafinil mouse menopause model 2021; marmoset MPTP model). Direct human MRI/MRS data on modafinil neuroprotection is sparse and inconclusive. Should not be considered a brain-protection compound — it's a wakefulness compound that may have some downstream protective effects but is not the right tool for Dylan's MMA-TBI brain-protection thesis (Cerebrolysin, DHA, citicoline, NAC are the right tools there).

▸ Verdict change log
  • 2026-05-05 — Initial verdict: STRONG-CANDIDATE (medium confidence). Established as reasonable A/B test candidate vs modafinil for week 8-12 of Dylan's V5 protocol, but modafinil 100 mg AM remains the more conservative daily-driver default for late chronotype migrating bedtime earlier. Verdict pending A/B test outcome.
▸ Open questions / gaps Open
  • No head-to-head subjective preference RCT comparing modafinil and armodafinil at clinically equipotent doses (200 mg modafinil vs 150 mg armodafinil) — published preference data is patient-anecdotal only.
  • No cognitive-enhancement RCT in healthy adults using armodafinil specifically; all cognitive enhancement evidence is extrapolated from modafinil.
  • No long-term (>12 months) outcome data on cognitive enhancement use specifically (vs sleep-disorder use).
  • No human MRI / fMRI long-term armodafinil data to confirm or refute brain plasticity / neuroprotection signals from animal work.
  • Pharmacogenomic dosing guidelines absent — CYP3A4 / CYP2C19 polymorphism effects on armodafinil exposure are inferred, not validated by dose-adjustment studies.
  • Question for Dylan post-A/B: if armodafinil wins on cognition but loses on sleep, can it work as a 2-3×/week tool for specific high-output days while modafinil stays the daily driver?
  • Customs interception risk for Indian-pharmacy modafinil/armodafinil is poorly quantified post-2024; current vendor reship guarantees suggest seizure rate <10% but specific data hard to find.
▸ Sources (full, with our context)
Back to compact view